Cell Therapy

The development of a connected nationwide ecosystem for cellular therapy is designed to standardize the quality of regenerative care across every Malaysian state. This ambitious shift is currently reshaping the biotechnology sector, where the focus has moved from being a passive consumer of

The inherent inefficiencies of the autologous model are tied to a one-batch-per-patient approach that restricts throughput and maintains high market prices for oncology treatments. While Chimeric Antigen Receptor (CAR) T-cell therapies have redefined oncology by providing life-saving results for

The ability to detect regulatory signals in rare cell states provides a functional hypothesis-generating resource for prioritizing causal variants in large-scale genetic studies. Scientists have long observed that two individuals of similar age and health can experience radically different outcomes

Novartis and Bristol Myers Squibb have inadvertently set a new precedent for transparency as they navigate the complex safety challenges of applying oncology tools to chronic autoimmune diseases. This strategic pivot reflects a broader industry realization that the risk-benefit calculus for

Industry groups are requesting concrete examples of how prior clinical data can be used to optimize dosing and streamline trial designs for rare disease therapies. This collective push follows the release of the Food and Drug Administration's draft guidance concerning the use of prior knowledge in

The recent observation of motor skill improvement and reduced chronic fatigue in multiple sclerosis patients marks a potential turning point in immunotherapy research. For years, the scientific community focused on Chimeric Antigen Receptor T-cell therapy as a weapon against terminal blood cancers,